论文部分内容阅读
目的探讨健脾利湿汤联合双歧杆菌三联活菌胶囊治疗溃疡性结肠炎的临床疗效及其对血清炎性因子的影响。方法将88例溃疡性结肠炎患者采用随机数字表法分为观察组和对照组各44例。对照组予健脾利湿汤治疗,观察组采用健脾利湿汤联合双歧杆菌三联活菌胶囊治疗,疗程4周。观察2组临床疗效及治疗前后血清炎性因子水平变化。结果观察组总有效率为93.18%,显著高于对照组的79.55%(χ2=8.70,P<0.05)。观察组治疗后肿瘤坏死因子α(TNF-α)、白介素8(IL-8)和C反应蛋白(CRP)水平均较治疗前和对照组治疗后显著降低(P<0.05),而IL-10水平较治疗前和对照组治疗后显著升高(P<0.05)。2组治疗期间均未发现明显不良反应。结论健脾利湿汤联合双歧杆菌三联活菌胶囊治疗溃疡性结肠炎效果显著,可明显改善患者的临床症状,抑制炎性因子,且安全性好。
Objective To investigate the clinical efficacy of Jianpi Lishi Decoction combined with Bifidobacterium triple viable capsule in the treatment of ulcerative colitis and its effect on serum inflammatory factors. Methods A total of 88 patients with ulcerative colitis were randomly divided into observation group and control group with 44 cases in each group. The control group was given Jianpi Lishi Decoction, and the observation group was treated with Jianpi Lishi Decoction combined with Bifidobacterium triple viable capsule for 4 weeks. The clinical curative effect and changes of serum inflammatory factors before and after treatment were observed. Results The total effective rate in the observation group was 93.18%, significantly higher than 79.55% in the control group (χ2 = 8.70, P <0.05). The levels of tumor necrosis factor α (TNF-α), interleukin 8 (IL-8) and C-reactive protein (CRP) in the observation group were significantly lower than those before treatment and in the control group The levels were significantly higher than those before treatment and those in the control group (P <0.05). No significant adverse reactions were found during the two groups. Conclusion Jianpi Lishi Decoction combined with Bifidobacterium triple viable capsule treatment of ulcerative colitis significantly, can significantly improve the clinical symptoms of patients, inhibit inflammatory cytokines, and good safety.